Cargando…
Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report
RATIONALE: Relapsed or refractory acute lymphoblastic leukemia poses a significant clinical challenge due to its poor prognosis, showing survival rates of less than a year even with the use of novel therapies. In this report, we describe the safe and effective use of trametinib combined with dasatin...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238268/ https://www.ncbi.nlm.nih.gov/pubmed/34160436 http://dx.doi.org/10.1097/MD.0000000000026440 |
_version_ | 1783714868686225408 |
---|---|
author | Wang, Jing Shen, Shu-Hong Hu, Bin-Fei Wang, Guan-Ling |
author_facet | Wang, Jing Shen, Shu-Hong Hu, Bin-Fei Wang, Guan-Ling |
author_sort | Wang, Jing |
collection | PubMed |
description | RATIONALE: Relapsed or refractory acute lymphoblastic leukemia poses a significant clinical challenge due to its poor prognosis, showing survival rates of less than a year even with the use of novel therapies. In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL). To the best of our knowledge, this is the first report on the successful use of 2 targeted drugs such as trametinib and dasatinib in a pediatric patient with Ph+ ALL and recurrent pancreatitis. PATIENT CONCERNS: A 6-year-old boy with ALL and Philadelphia chromosome (Ph+) who had recurrent asparaginase-associated pancreatitis. DIAGNOSIS: The patient was diagnosed with ALL, based on clinical features, laboratory analyses, bone marrow aspiration evaluation in morphology, immunology, cytogenetics, and molecular. INTERVENTIONS: The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy. However, owing to recurrent asparaginase-associated pancreatitis, the patient has to abandon asparaginase in consolidation. Considering the high risk of relapse, we used trametinib and dasatinib combined with chemotherapy as maintenance chemotherapy. OUTCOMES: After 6 months, there were no obvious side effects or residual disease. LESSONS: We suggest that the combination of trametinib and dasatinib may represent a viable option to treat patients with potential relapsed/refractory Ph+ ALL. |
format | Online Article Text |
id | pubmed-8238268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-82382682021-07-06 Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report Wang, Jing Shen, Shu-Hong Hu, Bin-Fei Wang, Guan-Ling Medicine (Baltimore) 4800 RATIONALE: Relapsed or refractory acute lymphoblastic leukemia poses a significant clinical challenge due to its poor prognosis, showing survival rates of less than a year even with the use of novel therapies. In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL). To the best of our knowledge, this is the first report on the successful use of 2 targeted drugs such as trametinib and dasatinib in a pediatric patient with Ph+ ALL and recurrent pancreatitis. PATIENT CONCERNS: A 6-year-old boy with ALL and Philadelphia chromosome (Ph+) who had recurrent asparaginase-associated pancreatitis. DIAGNOSIS: The patient was diagnosed with ALL, based on clinical features, laboratory analyses, bone marrow aspiration evaluation in morphology, immunology, cytogenetics, and molecular. INTERVENTIONS: The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy. However, owing to recurrent asparaginase-associated pancreatitis, the patient has to abandon asparaginase in consolidation. Considering the high risk of relapse, we used trametinib and dasatinib combined with chemotherapy as maintenance chemotherapy. OUTCOMES: After 6 months, there were no obvious side effects or residual disease. LESSONS: We suggest that the combination of trametinib and dasatinib may represent a viable option to treat patients with potential relapsed/refractory Ph+ ALL. Lippincott Williams & Wilkins 2021-06-25 /pmc/articles/PMC8238268/ /pubmed/34160436 http://dx.doi.org/10.1097/MD.0000000000026440 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 4800 Wang, Jing Shen, Shu-Hong Hu, Bin-Fei Wang, Guan-Ling Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report |
title | Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report |
title_full | Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report |
title_fullStr | Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report |
title_full_unstemmed | Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report |
title_short | Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report |
title_sort | successful use of trametinib and dasatinib combined with chemotherapy in the treatment of ph-positive b-cell acute lymphoblastic leukemia: a case report |
topic | 4800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238268/ https://www.ncbi.nlm.nih.gov/pubmed/34160436 http://dx.doi.org/10.1097/MD.0000000000026440 |
work_keys_str_mv | AT wangjing successfuluseoftrametinibanddasatinibcombinedwithchemotherapyinthetreatmentofphpositivebcellacutelymphoblasticleukemiaacasereport AT shenshuhong successfuluseoftrametinibanddasatinibcombinedwithchemotherapyinthetreatmentofphpositivebcellacutelymphoblasticleukemiaacasereport AT hubinfei successfuluseoftrametinibanddasatinibcombinedwithchemotherapyinthetreatmentofphpositivebcellacutelymphoblasticleukemiaacasereport AT wangguanling successfuluseoftrametinibanddasatinibcombinedwithchemotherapyinthetreatmentofphpositivebcellacutelymphoblasticleukemiaacasereport |